Intervention
sildenafil
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 27 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
27 shownSildenafil Activates Browning of White Adipose and Improves Insulin SensitivityNCT02524184 · 2015-08-01
UNKNOWNCharacterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.NCT01800292 · 2013-02-01
COMPLETEDSildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary HypertensionNCT00730067 · 2012-06-01
WITHDRAWNSildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac SurgeryNCT01481350 · 2012-02-01
COMPLETEDA Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesNCT01244620 · 2010-11-01
TERMINATEDEffects of Sildenafil in Resistant Hypertensives and Genetic PolymorphismNCT01392638 · 2010-07-01
COMPLETEDA Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial HypertensionNCT00853112 · 2009-04-01
TERMINATEDDoes Sildenafil Increase Exercise Performance in Air Pollution?NCT00808912 · 2008-12-01
COMPLETEDSildenafil IV Bolus StudyNCT00800592 · 2008-10-01
COMPLETEDPharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusNCT00478335 · 2007-05-01
COMPLETEDSildenafil and Exercise Capacity in HypertensionNCT00599235 · 2007-03-01
COMPLETEDPulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With SildenafilNCT00625079 · 2007-02-01
WITHDRAWNCombination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerNCT00752115 · 2007-02-01
COMPLETEDEffects of Viagra on Heart Function in Patients With Heart FailureNCT00781508 · 2006-12-01
COMPLETEDSildenafil Study to Treat Idiopathic Pulmonary FibrosisNCT00359736 · 2006-07-01
COMPLETEDTo Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 WeeksNCT00946114 · 2006-06-01
COMPLETEDChronic Sildenafil for Severe Diaphragmatic HerniaNCT00133679 · 2006-02-01
TERMINATEDPDE5-Inhibition With Sildenafil in Chronic Heart FailureNCT00407446 · 2004-01-01
COMPLETEDSildenafil and Pulmonary Artery PressureNCT00145938 · 2003-09-01
TERMINATEDStudy of Sildenafil in Advanced Heart Failure.NCT00309790 · 2003-05-01
COMPLETEDA Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 DiabetesNCT00645268 · 2002-12-01
COMPLETEDA Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial HypertensionNCT00644605 · 2002-10-01
COMPLETEDSildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's DiseaseNCT02162979 · 2002-02-01
TERMINATEDStudy of Sildenafil in Patient With Heart Failure.NCT00309816 · 2001-12-01
COMPLETEDStudy of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in WomenNCT00375297 · 2001-01-01
COMPLETEDEffect of Chronic PDE5-Inhibition on Endothelial Function in DiabeticsNCT00420901 · 1999-01-01
COMPLETEDSildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With SildenafilNCT01897740
NO_LONGER_AVAILABLECommon conditions
Pulmonary Hypertension6Hypertension, Pulmonary5Pulmonary Arterial Hypertension3Congestive Heart Failure2Heart Failure2Hypertension2Air Pollution1Alveolitis, Fibrosing1COPD1Depression1Diabetes1Diabetes Mellitus, Type 21Erectile Dysfunction1Exercise Performance1Fibrosis, Pulmonary1Hernia, Diaphragmatic1Hypertension, Pulmonary Artery1Hypoplasia, Pulmonary1Idiopathic Pulmonary Fibrosis1Interstitial Lung Disease1Left Ventricular Dysfunction1Nephrogenic Diabetes Insipidus1Non-small Cell Lung Cancer1Obesity1Parkinson's Disease1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
pulmonary hypertension9pulmonary arterial hypertension3congestive heart failure2heart failure2chronic obstructive pulmonary disease1depressive disorder1diabetes mellitus1erectile dysfunction1interstitial lung disease1nephrogenic diabetes insipidus1non-small cell lung carcinoma1obesity disorder1Parkinson disease1pulmonary hypoplasia1type 2 diabetes mellitus1
Leading sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
5
Massachusetts General Hospital
2
Pfizer
2
Hamamatsu University
1
IRCCS San Raffaele
1
Loma Linda University
1
Marywood University
1
MetroHealth Medical Center
1
University of Aarhus
1
University of Arizona
1
University of California, Los Angeles
1
University of California, San Francisco
1
University of Campinas, Brazil
1
University of Chicago
1
University of Colorado, Denver
1
Trial status mix
COMPLETED18
TERMINATED5
WITHDRAWN2
NO_LONGER_AVAILABLE1
UNKNOWN1
Phase mix
PHASE48
PHASE26
PHASE36
NA4
PHASE12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.